Type 2 diabetes specialist care in Italy in the AMD Annals initiative 2024: The path is traced

IF 6.1 3区医学 Q1 ENDOCRINOLOGY & METABOLISM

Diabetes research and clinical practice Pub Date : 2025-05-21 DOI:10.1016/j.diabres.2025.112273

G.T. Russo , S. De Cosmo , A. Nicolucci , V. Manicardi , A. Rocca , G. Lucisano , M.C. Rossi , P. Di Bartolo , G. Di Cianni , R. Candido , AMD Annals Study Group (the full list of participants is reported as supplementary material)

{"title":"Type 2 diabetes specialist care in Italy in the AMD Annals initiative 2024: The path is traced","authors":"G.T. Russo , S. De Cosmo , A. Nicolucci , V. Manicardi , A. Rocca , G. Lucisano , M.C. Rossi , P. Di Bartolo , G. Di Cianni , R. Candido , AMD Annals Study Group (the full list of participants is reported as supplementary material)","doi":"10.1016/j.diabres.2025.112273","DOIUrl":null,"url":null,"abstract":"<div><h3>Aims</h3><div>The AMD Annals initiative, active in Italy since 2006, monitors diabetes care quality, showing continuous improvements through standardized indicators. This report presents the 2024 data on type 2 diabetes (T2D).</div></div><div><h3>Methods</h3><div>Approximately half of the Italian diabetes centers annually extract anonymized electronic medical records data. Process, treatment and outcome indicators, and the Q-score, a validated score of overall care, were evaluated.</div></div><div><h3>Results</h3><div>Data from 301 centers on 680,122 T2D patients (58.6 % men, mean age 69.9 years; 35.9 % > 75 years) were evaluated. HbA1c ≤ 7.0 % was achieved by 55.9 % of patients, LDL < 70 mg/dl by 44.6 %, blood pressure (BP) < 130/80 mmHg by 26.5 %, with 7.7 % meeting multiple targets. Obesity showed a prevalence of 35 %, while smoking was high (17.9 %). Pharmacological treatment improved: 72.0 % used lipid-lowering drugs, 68.8 % BP-lowering, and 97.6 % glucose-lowering drugs. As for innovative drugs, 41.9 % of patients were treated with SGLT2i and 35.5 % with GLP1 RA, with an increasing trend compared to 2023 data. Complication rates remained stable, with a further Q-score improvement.</div></div><div><h3>Conclusions</h3><div>The 2024 data confirm ongoing improvements in T2D care, despite an aging population. Although gaps persist, the path toward aligning practice with guidelines is well established.</div></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"225 ","pages":"Article 112273"},"PeriodicalIF":6.1000,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes research and clinical practice","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0168822725002876","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Aims

The AMD Annals initiative, active in Italy since 2006, monitors diabetes care quality, showing continuous improvements through standardized indicators. This report presents the 2024 data on type 2 diabetes (T2D).

Methods

Approximately half of the Italian diabetes centers annually extract anonymized electronic medical records data. Process, treatment and outcome indicators, and the Q-score, a validated score of overall care, were evaluated.

Results

Data from 301 centers on 680,122 T2D patients (58.6 % men, mean age 69.9 years; 35.9 % > 75 years) were evaluated. HbA1c ≤ 7.0 % was achieved by 55.9 % of patients, LDL < 70 mg/dl by 44.6 %, blood pressure (BP) < 130/80 mmHg by 26.5 %, with 7.7 % meeting multiple targets. Obesity showed a prevalence of 35 %, while smoking was high (17.9 %). Pharmacological treatment improved: 72.0 % used lipid-lowering drugs, 68.8 % BP-lowering, and 97.6 % glucose-lowering drugs. As for innovative drugs, 41.9 % of patients were treated with SGLT2i and 35.5 % with GLP1 RA, with an increasing trend compared to 2023 data. Complication rates remained stable, with a further Q-score improvement.

Conclusions

The 2024 data confirm ongoing improvements in T2D care, despite an aging population. Although gaps persist, the path toward aligning practice with guidelines is well established.

查看原文本刊更多论文

AMD年鉴倡议2024在意大利的2型糖尿病专科护理：路径被追踪

自2006年以来，AMD年鉴倡议在意大利活跃，监测糖尿病护理质量，通过标准化指标显示持续改进。本报告介绍了2024年2型糖尿病（T2D）的数据。方法：大约一半的意大利糖尿病中心每年提取匿名电子病历数据。评估过程、治疗和结果指标以及总体护理的有效评分Q-score。结果来自301个中心的680122例T2D患者的数据(58.6%为男性，平均年龄69.9岁；35.9% >；75年)进行评估。55.9%的患者HbA1c≤7.0%,LDL <；70 mg/dl下降44.6%，血压（BP）和lt；130/80毫米汞柱降低26.5%，其中7.7%达到多个目标。肥胖患病率为35%，而吸烟患病率较高（17.9%）。药物治疗改善：72.0%使用降脂药物，68.8%使用降血压药物，97.6%使用降血糖药物。在创新药物方面，41.9%的患者接受了SGLT2i治疗，35.5%的患者接受了GLP1 RA治疗，与2023年的数据相比有上升趋势。并发症发生率保持稳定，q评分进一步提高。结论：2024年的数据证实，尽管人口老龄化，t2dm护理仍在不断改善。尽管差距依然存在，但使实践与指导方针保持一致的道路已经确立。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Diabetes research and clinical practice 医学-内分泌学与代谢

CiteScore

10.30

自引率

3.90%

发文量

862

审稿时长

32 days

期刊介绍： Diabetes Research and Clinical Practice is an international journal for health-care providers and clinically oriented researchers that publishes high-quality original research articles and expert reviews in diabetes and related areas. The role of the journal is to provide a venue for dissemination of knowledge and discussion of topics related to diabetes clinical research and patient care. Topics of focus include translational science, genetics, immunology, nutrition, psychosocial research, epidemiology, prevention, socio-economic research, complications, new treatments, technologies and therapy.